Time for a third-generation pneumococcal conjugate vaccine

Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries

“…A 10-valent PCV (PCV10; Synflorix TM ) and a 13-valent PCV (PCV13, Prevnar13 TM ) were introduced in Europe in 2009, and resulted in further reductions in IPD [11]. However, since then, the incidence of disease attributable to nonvaccine serotypes has risen, with some serotypes, such as serotypes 3 and 19A persisting [4,11,12] [13], both recently approved for use in adults in the US [14,15]. V114 contains all PCV13 serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and two additional serotypes, 22F and 33F [16,17].…”

A Narrative Review of the Molecular Epidemiology and Laboratory Surveillance of Vaccine Preventable Bacterial Meningitis Agents: Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae and Streptococcus agalactiae

“…In summary, we are in a much better position to control bacterial meningitis than ever before and surveillance continues to have a key role to play [69,70].…”

“…[68] appear to be just as relevant today after two decades of PCV use. Indeed, expert comments in 2021 still wrestle with the changing epidemiology of IPD due to shifting serotypes, and identify continuous surveillance as an important function in the control of IPD [69,70]. Ideally, a pan-pneumococcal universal vaccine would solve the problem of chasing after the emergence of non-vaccine serotypes as causes of IPD.…”

Comprehensive value assessments for new pediatric pneumococcal conjugate vaccines

“…There is currently an unmet need for new pneumococcal vaccines to address this residual disease burden [9], while maintaining suppression of serotypes in existing vaccines. Vaccines currently in late-stage clinical development include V114, an investigational 15-valent PCV (PCV15), and a 20-valent PCV [10].…”